 ROCKVILLE, Md., Dec. 22, 2020 GLOBE NEWSWIRE -- Supernus Pharmaceuticals, Inc. Nasdaq: SUPN, a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced positive topline results from a Phase III study of SPN-812 in adults P306 for the treatment of attention deficit hyperactivity disorder ADHD. 